DuPont Pharmaceuticals Develops TACE Inhibitor; Phase II Trials Beginning in North America and Europe

Apr 03, 2001, 01:00 ET from DuPont Pharmaceuticals Company

    WILMINGTON, Del., April 3 /PRNewswire/ -- DuPont Pharmaceuticals today
 announced that it is developing an oral Tumor Necrosis Factor (TNF) Alpha
 Converting Enzyme (TACE) inhibitor.  TACE is a new target implicated in the
 inflammatory process that is a factor in many diseases, such as rheumatoid
 arthritis, psoriasis and Crohn's disease.
     TACE is an enzyme that releases TNF, a key mediator of the inflammatory
 process.  While current biologics, such as Enbrel(R)(etanercept) and
 Remicade(R) (infliximab), bind to TNF sequestering it from circulation, the
 DuPont Pharmaceuticals compound prevents TNF production.  Enbrel(R) and
 Remicade(R) are administered by injection; the DuPont Pharmaceuticals compound
 would be taken orally.
     The mechanism of action of the compound was presented today at The 221st
 Annual Meeting of the American Chemical Society during a session where Paul S.
 Anderson, Ph.D., Senior Vice President, Chemical and Physical Sciences at
 DuPont Pharmaceuticals, was honored with the American Chemical Society's Award
 in Industrial Chemistry.
     "We know that the biologics that neutralize TNF are very effective in a
 variety of diseases," said Paul A. Friedman MD, President, DuPont
 Pharmaceuticals Research Laboratories, Business Development and Strategic
 Planning.  "To have identified a small molecule that is potent and orally
 bioavailable and prevents the production of TNF is a testament to the world-
 class medicinal chemistry being conducted at DuPont Pharmaceuticals under Paul
 Anderson."
     Phase II trials in patients with rheumatoid arthritis (RA) are beginning
 in North America and Europe.  RA is an inflammatory autoimmune disease that
 affects approximately one percent of the world's population.  Applications for
 marketing approval for this indication could be submitted as early as 2004.
     DuPont Pharmaceuticals Company, a wholly owned subsidiary of DuPont, is a
 worldwide business focused on research, development and delivery of
 pharmaceuticals and imaging agents to treat unmet medical needs in the fights
 against HIV/AIDS, cardiovascular disease, inflammatory diseases, cancer and
 neurological diseases.
     DuPont (NYSE:   DD) is a science company, delivering science-based solutions
 that make a difference in people's lives in food and nutrition; health care;
 apparel; home and construction; electronics; and transportation.  Founded in
 1802, the company operates in 70 countries and has 93,000 employees.
 
     Enbrel(R)(etanercept) is a registered trademark of Immunex Corporation.
     Remicade(R)(infliximab) is a registered trademark of Centocor.
 
 

SOURCE DuPont Pharmaceuticals Company
    WILMINGTON, Del., April 3 /PRNewswire/ -- DuPont Pharmaceuticals today
 announced that it is developing an oral Tumor Necrosis Factor (TNF) Alpha
 Converting Enzyme (TACE) inhibitor.  TACE is a new target implicated in the
 inflammatory process that is a factor in many diseases, such as rheumatoid
 arthritis, psoriasis and Crohn's disease.
     TACE is an enzyme that releases TNF, a key mediator of the inflammatory
 process.  While current biologics, such as Enbrel(R)(etanercept) and
 Remicade(R) (infliximab), bind to TNF sequestering it from circulation, the
 DuPont Pharmaceuticals compound prevents TNF production.  Enbrel(R) and
 Remicade(R) are administered by injection; the DuPont Pharmaceuticals compound
 would be taken orally.
     The mechanism of action of the compound was presented today at The 221st
 Annual Meeting of the American Chemical Society during a session where Paul S.
 Anderson, Ph.D., Senior Vice President, Chemical and Physical Sciences at
 DuPont Pharmaceuticals, was honored with the American Chemical Society's Award
 in Industrial Chemistry.
     "We know that the biologics that neutralize TNF are very effective in a
 variety of diseases," said Paul A. Friedman MD, President, DuPont
 Pharmaceuticals Research Laboratories, Business Development and Strategic
 Planning.  "To have identified a small molecule that is potent and orally
 bioavailable and prevents the production of TNF is a testament to the world-
 class medicinal chemistry being conducted at DuPont Pharmaceuticals under Paul
 Anderson."
     Phase II trials in patients with rheumatoid arthritis (RA) are beginning
 in North America and Europe.  RA is an inflammatory autoimmune disease that
 affects approximately one percent of the world's population.  Applications for
 marketing approval for this indication could be submitted as early as 2004.
     DuPont Pharmaceuticals Company, a wholly owned subsidiary of DuPont, is a
 worldwide business focused on research, development and delivery of
 pharmaceuticals and imaging agents to treat unmet medical needs in the fights
 against HIV/AIDS, cardiovascular disease, inflammatory diseases, cancer and
 neurological diseases.
     DuPont (NYSE:   DD) is a science company, delivering science-based solutions
 that make a difference in people's lives in food and nutrition; health care;
 apparel; home and construction; electronics; and transportation.  Founded in
 1802, the company operates in 70 countries and has 93,000 employees.
 
     Enbrel(R)(etanercept) is a registered trademark of Immunex Corporation.
     Remicade(R)(infliximab) is a registered trademark of Centocor.
 
 SOURCE  DuPont Pharmaceuticals Company